Babies born in 50 years’ time could live until they are 150, according to reports last week. Anti-ageing technology is apparently developing so fast that only those with eight decades under their belts will be able to claim a mid-life-crisis Ferrari in the future.
I’m not yet convinced — this certainly isn’t a sell note on listed undertaker Dignity. But what is clear is that while we are living longer, our brains can’t always keep up.
Aim-listed neuroscience tech firm Cambridge Cognition Holdings knows all about that. The brain-focused business, founded more than 30 years ago and spun out of research at Cambridge University, isn’t a drug developer or a straight pharma play. It makes specialist software for tasks such as designing clinical trials, and